| Candidate Product | Molecular Targets | Indications | Development Stage | |
|---|---|---|---|---|
| Macromolecular Drugs | KY-0118 | Dual functional IL2 fusion protein targeting PD-1 (Monotherapy) | Advanced solid tumors（Intravenous/Subcutaneous Injection） | Clinical Trial Phase I b Phase I |
| Advanced solid tumors（Subcutaneous Drug Administration in the Drainage Area) | Phase I b  | |||
Dual functional IL2 fusion protein targeting PD-1 (Monoclonal antibody combined PD-L1) | Advanced solid tumors (colorectal cancer, NSCLC) | Clinical Trial Phase I b Phase I | ||
KY-0301 | MET-EGFR dual target ADC | Advanced solid tumors (Lung cancer / head and neck cancer) | Clinical Trial Phase I Phase I | |
KY-0601 | B7H3-cMET dual target ADC | Advanced solid tumors (CRC/esophagus cancer) | PCC | |
| KY-0901 | Bispecific nanobody drug conjugate with dual payloads | Advanced solid tumors ( pancreatic cancer / cholangiocarcinoma, etc. | PCC | |
| CAR-T | KQ-2003 | BCMA×CD19 | Recurrent/Refractory multiple myeloma | Clinical Trial Phase Ⅰb
|
| POEMS | Clinical Trial Phase Ⅰ/Ⅱ a |
